1. Home
  2. ENTX vs RVPH Comparison

ENTX vs RVPH Comparison

Compare ENTX & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • RVPH
  • Stock Information
  • Founded
  • ENTX 2010
  • RVPH 2006
  • Country
  • ENTX Israel
  • RVPH United States
  • Employees
  • ENTX N/A
  • RVPH N/A
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • RVPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • ENTX Health Care
  • RVPH Health Care
  • Exchange
  • ENTX Nasdaq
  • RVPH Nasdaq
  • Market Cap
  • ENTX 90.2M
  • RVPH 88.0M
  • IPO Year
  • ENTX 2018
  • RVPH N/A
  • Fundamental
  • Price
  • ENTX $2.27
  • RVPH $1.79
  • Analyst Decision
  • ENTX Strong Buy
  • RVPH Strong Buy
  • Analyst Count
  • ENTX 1
  • RVPH 5
  • Target Price
  • ENTX $10.00
  • RVPH $11.40
  • AVG Volume (30 Days)
  • ENTX 77.1K
  • RVPH 1.6M
  • Earning Date
  • ENTX 03-07-2025
  • RVPH 11-14-2024
  • Dividend Yield
  • ENTX N/A
  • RVPH N/A
  • EPS Growth
  • ENTX N/A
  • RVPH N/A
  • EPS
  • ENTX N/A
  • RVPH N/A
  • Revenue
  • ENTX $99,000.00
  • RVPH N/A
  • Revenue This Year
  • ENTX N/A
  • RVPH N/A
  • Revenue Next Year
  • ENTX N/A
  • RVPH N/A
  • P/E Ratio
  • ENTX N/A
  • RVPH N/A
  • Revenue Growth
  • ENTX 607.14
  • RVPH N/A
  • 52 Week Low
  • ENTX $0.95
  • RVPH $0.60
  • 52 Week High
  • ENTX $3.35
  • RVPH $4.50
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 48.84
  • RVPH 44.85
  • Support Level
  • ENTX $2.20
  • RVPH $1.66
  • Resistance Level
  • ENTX $2.49
  • RVPH $1.88
  • Average True Range (ATR)
  • ENTX 0.21
  • RVPH 0.15
  • MACD
  • ENTX -0.01
  • RVPH -0.03
  • Stochastic Oscillator
  • ENTX 50.00
  • RVPH 25.51

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

Share on Social Networks: